Doença coronária no paciente com doença renal crônica

Emerson de Albuquerque Seixas; Luis Cuadrado Martin

doi:10.5327/Z1984-4840201626519

Autores

Emerson de Albuquerque Seixas FCMS/PUC-SP
Luis Cuadrado Martin FCMS/PUC-SP

DOI:

https://doi.org/10.5327/Z1984-4840201626519

Palavras-chave:

insuficiência renal crônica, doenças cardiovasculares, doença da artéria coronariana

Resumo

As doenças cardiovasculares representam a maior causa de mortalidade nos pacientes renais crônicos no pré e pós-transplante renal. Dentre elas, a doença coronariana apresenta destaque especial. Preditores de risco têm sido usados no seu diagnóstico, que é desafiador. O presente trabalho constitui artigo de atualização a respeito da fisiopatologia, do diagnóstico, do prognóstico e do manejo terapêutico da doença coronária na doença renal crônica.

Downloads

Não há dados estatísticos.

Metrics

Carregando Métricas ...

Biografia do Autor

Emerson de Albuquerque Seixas, FCMS/PUC-SP

Professor do Depto. de Medicina FCMS/PUC-SP

Luis Cuadrado Martin, FCMS/PUC-SP

Professor do Depto. Medicina da Faculdade de Medicina UNESP

Referências

Hoerger TJ, Simpson SA, Yarnoff BO, Pavkov ME, Burrows NR, Saydah SH, et al. The Future Burden of CKD in the United States: A Simulation Model for the CDC CKD Initiative. Am J Kidney Dis. 2015;65(3):403-11.

Center for Disease Control and Prevention. Chronic Kidney Disease (CKD) Surveillance Project [Internet]. Atlanta: CDC; 2015 [acesso em 02 nov. 2015]. Disponível em: http://nccd.cdc.gov/ckd

Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol. 2009;53:2129-40.

Le A, Wilson R, Douek K, Pulliam L, Tolzman D, Norman D, et al. Prospective risk stratification in renal transplant candidates for cardiac death. Am J Kidney Dis. 1994;24:65-71.

Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003;108:2154-69.

Martin LC, Franco RJS. A doença renal como fator de risco cardiovascular. Arq Bras Cardiol. 2005;85:432-6.

Lewis MS, Wilson RA, Walker KW, Wilson DJ, Norman DJ, Barry JM, et al. Validation of an algorithm for predicting cardiac events in renal transplant candidates. Am J Cardiol. 2002;89:847-50.

Stewart G, Jardine AG, Briggs JD. Ischaemic heart disease following renal transplantation. Nephrol Dial Transplant 2000;15:269-77.

Jones DG, Taylor AM, Enkiri SA, Lobo P, Brayman KL, Keeley EC, et al. Extent and severity of coronary disease and mortality in patients with end-stage renal failure evaluated for renal transplantation. Am J Transplant. 2009;9:1846-52.

Bucharles SGE, Varela AM, Barberato SH, Pecoits R. Avaliação e manejo da doença cardiovascular em pacientes com doença renal crônica. J Bras Nefrol. 2010;32(1):120-7.

Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002;13(7):1918-27.

Cachofeiro V, Goicochea M, Vinuesa SG, Oubina P, Lahera V, Luno J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl. 2008;S4-9

Lopes AA, Bragg-Gresham J L, Ramirez SPB, Andreucci VE, Akiba T, Saito A, et al. Prescription of antihypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS. Nephrol Dial Transplant. 2009;24:2809-16.

Cavalcante LG, Souza RC, Kochi AC, Okoshi K, Basan SG, Hueb JC, et al. Left ventricular mass behaviour in hemodialysis patients during 17 years. J Bras Nefrol. 2015;37(3):341-8.

Blicher TM, Hommel K, Olesen JB, Torp-Pedersen C, Madsen M, Kamper AL. Less use of standard guideline- based treatment of myocardial infarction in patients with chronic kidney disease: a Danish nation-wide cohort study. Eur Heart J. 2013;34(37):2916-23.

Nakao K, Makino H, Morita S, Takahashi Y, Akizawa T, Saito A, et al. Beta blocker prescription and outcomes in hemodialysis patients from The Japan Dialysis Outcomes and Practice Patterns Study. Nephron Clin Pract. 2009;113:c132–9.

Lentine KL, Costa SP , Weir MR, Robb JF, Fleisher LA, Kasiske BL, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2012;126:617-63.

Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-48.

Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-407.

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181-92.

Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336:645-51.

Lima JJG, Sabbaga E, Vieira MLC, Paula FJ, Ianhez LE, Krieger EM, et al. Coronary angiography is the best predictor of events in renal transplant candidates compared with noninvasive testing. Hypertension. 2003;42:263-8.

Libby P, Bonow RO, Mann DL, Zipes DP, Braunwald E. Braunwald’s heart disease a textbook of cardiovascular medicine. 8ª ed. Philadelphia: Saunders Elsevier; 2008. p. 206,253-5, 259-61, 376-8.

Rabbat CG, Treleaven DJ, Russel JD, Ludwin D, Cook DJ. Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: a meta- analysis. J Am Soc Nephrolol. 2003;14:431-9.

Lima JJG, Gowdak LHW, Paula FJ, Ramires JAF, Bortolotto LA. The role of myocardial scintigraphy in the assessment of cardiovascular risk in patients with end-stage chronic kidney disease on the waiting list for renal transplantation. Nephrol Dial Transplant. 2012;27:2979-84.

Gowdak LH, Paula FJ, César LA, Bortolotto LA, Lima JJ. A new risk score model to predict the presence of significant coronary artery disease in renal transplant candidates. Transplant Res. 2013;2(1):18.

Seixas EA, Carmello BL, Kojima CA, Contti MM, Andrade LGM, Maiello JR, et al. Frequency and clinical predictors of coronary artery disease in chronic renal failure renal transplant candidates. Ren Fail. 2015;37(4):597-600.

James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation. 2010;122:1056-67.

Hage FG, Smalheiser S, Zoghbi GJ, Perry GJ, Deierhoi M, Warnock D, et al. Predictors of survival in patients with end-stage renal disease evaluated for kidney transplantation. Am J Cardiol. 2007;100:1020-5.

Sedlis SP, Jurkovitz CT, Hartigan PM, Goldfarb DS, Lorin JD, Dada M, et al. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. Am J Cardiol. 2009;104:1647-53.